Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

UPTAKE - Virtuele zorg: virtueel thuisziekenhuis met bewaking op afstand om ziekenhuisopnames in acute zorg te verminderen (UPTAKE-VC)

5 november 2026 bijgewerkt door: University of Calgary

Gebruik van gepersonaliseerde risico- en digitale hulpmiddelen om transities na acute niergebeurtenissen te begeleiden - Virtuele zorg: virtueel thuisziekenhuis met monitoring op afstand om ziekenhuisopnames in acute zorg te verminderen

Method: Randomized Controlled Trial Study Duration: 3 Years Study Centre(s) University of Calgary and University of Alberta Objectives: To fill care gaps by implementing strategies to reduce length of hospital stay, readmission rates, and improve long-term outcomes after Acute Kidney Injury (AKI). Number of Participants: Three Hundred and fifty four (n=354) Diagnosis and Main Inclusion Criteria: Hospitalized adults with AKI at high risk of hospital readmission or death

Study Intervention: Multi-component Digital Health Solutions, including:

  1. Computerized Clinical Decision Support (CDS) and
  2. Virtual Care Delivered through Hospital at Home (VC) Duration of administration: Determined by the Patient's clinical team Reference therapy: Usual Care Statistical Analyses: Descriptive Analysis, Regression

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

  1. Background and Rationale

    Acute kidney injury (AKI) is a common and serious complication in hospitals. A major care gap for survivors of AKI is the fragmentation of care that exists as they transition from the hospital to their home. This contributes to a high risk of adverse long-term outcomes, including prolonged hospitalization, high rates of readmission, cardiovascular events, infections, progression to chronic kidney disease (CKD), kidney failure requiring dialysis, and death.

    To address this challenge, the investigators are implementing multi-component digital health solutions including Computerized Clinical Decision Support (CDS) and Digital Remote Patient Monitoring (dRPM) through Virtual Care (VC) programs in Alberta to reduce length of hospital stay and readmission rates and improve long-term outcomes after AKI.

    Evidence of the effectiveness of the two digital health solutions is available from Alberta and international clinical trials. Our team previously implemented a computerized CDS intervention for AKI risk assessment and prevention and achieved improved AKI prevention and reduced AKI incidence after cardiac procedures across the province. The investigators will use a similar approach to identify high risk patients with AKI and provide recommendations to improve the quality of their care, which is well suited to the evolving digital health infrastructure in Alberta.

    Providing hospital-level care at home through Virtual Care (VC) teams has been shown to reduce mortality and readmission rates. Alberta's VC program have existed in both Edmonton and Calgary since 2018 and have reported lower readmission rates, Emergency Department (ED) visits and use of Emergency Medical Services than observed with usual care. Patients reported that the program helped them regain their independence and function. Alberta's VC programs have implemented dRPM technology, which has been further associated with fewer days in hospital and emergency department visits. Patients reported better quality of care using this technology. The framework for dRPM and complex care planning is already in place in Alberta's Virtual Care programs. The investigators intend to utilize these programs to improve transitions of care through early facilitated discharge and enhanced follow-up of patients with AKI at high risk of hospital readmission, who require frequent monitoring and more intensive care strategies during this vulnerable period of transition in care.

  2. Research Question and Objectives

    • Implement and evaluate a transition of care intervention for patients with AKI.
    • Integrate digital health solutions that can achieve levels of monitoring and care in a patient's own home that are comparable to acute care, while transitioning care to the community setting.
    • Reduce the length of hospital stay and risk of hospital readmission for people with AKI.
    • Improve the long-term outcomes after hospitalization with AKI.
  3. Methods

The investigators will evaluate implementation initially in a Vanguard phase to establish feasibility and acceptability of the intervention, followed by an evaluation of implementation and effectiveness of the intervention in a larger Multicenter Randomized Controlled Trial (RCT). High risk patients with AKI and a predicted risk of readmission or death ≥20% will be identified using a Best Practice Alert (BPA) in Connect Care and participants will be randomized to care with or without virtual monitoring through the VC programs. All patients will receive the same baseline interventions refined in the Vanguard phase, while the intervention arm will additionally receive VC with dRPM following discharge.

High risk patients in the intervention arm will be navigated through the transition of care pathway by a trained nurse navigator. Patients will receive dRPM kits, and biometric data will be automatically uploaded to the web-based monitoring platform and reviewed by the nurse navigator. Patients will receive regular virtual assessments via telephone or videoconferencing (via the tablet) after in-patient discharge. Blood tests will be drawn at home by community paramedics as deemed necessary by the clinical team to assess kidney function and monitor for complications of AKI. Should concerns be identified that warrant in-person assessment, paramedic care teams will be sent for assessment and/or intervention. Upon completion of the intervention patients will be assessed for readiness to move to the subacute arms of the program and return to their primary care provider. If ongoing nephrologist or other specialist care is required, the nurse navigator will ensure appropriate follow up is arranged.

Studietype

Ingrijpend

Inschrijving (Geschat)

354

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Alberta
      • Calgary, Alberta, Canada, T2N 1N4
        • Werving
        • University of Calgary
        • Contact:
        • Hoofdonderzoeker:
          • Matthew T James, MD PhD FRCPC
      • Edmonton, Alberta, Canada, T6G 2G3
        • Werving
        • University of Alberta
        • Contact:
        • Hoofdonderzoeker:
          • Neesh Pannu, MD SM FRCPC

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Age ≥ 18 years old.
  • AKI identified in hospital using Kidney Disease Improving Global Outcomes (KDIGO) criteria17.
  • Hospitalization > 48 hours.
  • LACE (L= Length patient Stay in the hospital, A= Acuity of Admission of patient in the hospital, C= Comorbidity and E= Emergency Visit.) Score 12 or higher.
  • Meets all inclusion criteria of Virtual Home Hospital programs of Calgary and Edmonton zones.

Exclusion Criteria:

  • Non-Alberta residents.
  • Resides outside the catchment areas for the Calgary and Edmonton Virtual Home Hospital programs.
  • C1 or C2 goals of care.
  • Hospitalization > 30 days.
  • Will be discharged to long-term care.
  • Kidney failure receiving dialysis.
  • Already admitted in Virtual Home Hospital Program

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Onderzoek naar gezondheidsdiensten
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Virtual Care

Participants will receive virtual care through Virtual Home Hospital programs in Alberta for their hospital to home transition of care.

Participants will go through Virtual hospital programs following the processes established by these programs in Alberta.

Geen tussenkomst: Usual Care

Participants will be discharged as per usual care practices from hospital to their home.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
the number of days alive out of hospital
Tijdsspanne: Up to 45 days from the date of randomization

the number of days alive out of hospital

Up to 45 days from the date of randomization

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
the time as inpatient in hospital
Tijdsspanne: Up to 45 days from the date of randomization

the time as inpatient in hospital

Up to 45 days from the date of randomization
death
Tijdsspanne: from the date of randomization up to 45 days, or date of death from any cause, whichever came first,

death records from health administrative data.

from the date of randomization up to 45 days, or date of death from any cause, whichever came first,
hospital readmission
Tijdsspanne: Up to 45 days from the date of randomization

hospital readmission records from health administrative data.

Up to 45 days from the date of randomization
Emergency Department visits
Tijdsspanne: Up to 45 days from the date of randomization

Emergency Department visit records from health administrative data.

Up to 45 days from the date of randomization
Estimated Glomerular Filtration (eGFR)
Tijdsspanne: At 90 days after the date of randomization

eGFR

At 90 days after the date of randomization
Urine Albumin Creatinine Ration (ACR)
Tijdsspanne: At 90 days after the date of randomization

ACR laboratory test

At 90 days after the date of randomization
total number of physician visits
Tijdsspanne: Up to 45 days from the date of randomization

total number of physician visits

Up to 45 days from the date of randomization
number of physician visits by specialty
Tijdsspanne: Up to 45 days from the date of randomization

primary care vs. non-primary care

Up to 45 days from the date of randomization
Changes to medication prescription
Tijdsspanne: Up to 45 days from the date of randomization

Changes to medication prescription (including starting, stopping, or dose adjustment) of an Angiotensin-Converting Enzyme Inhibitors (ACEI)/Angiotensin receptor blockers (ARB), diuretic, SGLT2 inhibitor, or NSAID or administration of IV fluid

Up to 45 days from the date of randomization
laboratory testing
Tijdsspanne: Up to 45 days from the date of randomization

Number of creatinine/eGFR, electrolytes, and urine protein quantification

Up to 45 days from the date of randomization
patient experience care transition measure
Tijdsspanne: At 45 days after the date of randomization

Online Survey

At 45 days after the date of randomization
Euro Qol- 5 Dimension (EQ5D)
Tijdsspanne: At 45 days after the date of randomization

Online Survey to assess quality of life mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from "no problems" to "extreme problems

At 45 days after the date of randomization

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Matthew James, MD, University of Calgary

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

10 augustus 2024

Primaire voltooiing (Geschat)

30 juni 2027

Studie voltooiing (Geschat)

31 december 2027

Studieregistratiedata

Eerst ingediend

29 juli 2024

Eerst ingediend dat voldeed aan de QC-criteria

2 augustus 2024

Eerst geplaatst (Werkelijk)

5 augustus 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

10 november 2026

Laatste update ingediend die voldeed aan QC-criteria

5 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren